D. Ruether

发表

Changes in Survival Outcomes of Patients With Neuroendocrine Neoplasms Over the Past 15 Years

M. Sawyer, O. Abdel-Rahman, Truong-Minh Pham, 2022, American journal of clinical oncology.

The Canadian Uro‐Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone‐refractory prostate cancer progressing after mitoxantrone/prednisone

F. Saad, P. Karakiewicz, E. Winquist, 2008, BJU international.

Factors influencing yields of progenitor cells for allogeneic transplantation: optimization of G-CSF dose, day of collection, and duration of leukapheresis.

J. Luider, J. Klassen, J. Russell, 1997, Journal of hematotherapy.

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers

R. Paschke, Moosa Khalil, M. Eszlinger, 2021, European thyroid journal.

Canadian guideline on genetic screening for hereditary renal cell cancers.

S. Pautler, C. Gedye, S. Kamel‐Reid, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Unmet Needs of Adult Survivors of Childhood Cancers: Associations with Developmental Stage at Diagnosis, Cognitive Impairment, and Time from Diagnosis.

J. Giese-Davis, D. Ruether, K. Russell, 2018, Journal of adolescent and young adult oncology.

Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study

D. O’Sullivan, N. Basappa, S. North, 2022, CMAJ open.

Management of advanced kidney cancer: Canadian Kidney Cancer Forum 2013 Consensus Update: Canadian Kidney Cancer Forum 2013.

Ronald B. Moore, P. Black, C. Gedye, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Hypertension management in patients with renal cell cancer treated with anti-angiogenic agents.

E. Schiffrin, G. Bjarnason, C. Kollmannsberger, 2012, Current oncology.

Neoadjuvant chemotherapy should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer of the bladder (MIBC): A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process.

A. Zlotta, P. Black, S. Sridhar, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Canadian Urologic Oncology Group (CUOG) phase II multi-center study using docetaxel/prednisone in the second line setting for metastatic hormone-refractory prostate cancer in patients progressing after first line mitoxantrone/prednisone

F. Saad, E. Winquist, S. North, 2005 .

Canadian Consensus for Biomarker Testing and Treatment of TRK Fusion Cancer in Adults †

H. Feilotter, S. Banerji, M. Tsao, 2021, Current oncology.

Randomized phase II trial of irofulven (IROF)/prednisone (P), IROF/capecitabine (C)/P or mitoxantrone (M)/P in docetaxel-pretreated hormone refractory prostate cancer (HRPC) patients (pts).

J. Hainsworth, T. Ciuleanu, L. Hart, 2006, Journal of Clinical Oncology.

EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

David C. Smith, E. Plimack, M. Milowsky, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.

P. Albers, H. Scher, G. Heller, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PRACTICE GUIDELINE SERIES Report from the 13 th Annual Western Canadian Gastrointestinal Cancer

D. Schellenberg, E. Dixon, J. Pasieka, 2012 .

Sunitinib maintenance therapy after response to docetaxel in metastatic castration resistant prostate cancer (mCRPC)

M. Eliasziw, B. Eigl, E. Winquist, 2016, Investigational New Drugs.

Cohort profile: the Alberta Prostate Cancer Research Initiative (APCaRI) Registry and Biorepository facilitates technology translation to the clinic through the use of linked, longitudinal clinical and patient-reported data and biospecimens from men in Alberta, Canada

B. Donnelly, N. Usmani, J. Lewis, 2020, BMJ Open.

Report from the 13th annual Western canadian gastrointestinal cancer consensus conference; calgary, alberta; september 8-10, 2011.

D. Schellenberg, E. Dixon, J. Pasieka, 2012, Current oncology.

Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma

O. Bathe, C. Butts, D. Bigam, 2004, BMC Cancer.

Virtual Cancer Care During the COVID-19 Pandemic in Alberta: Evidence From a Mixed Methods Evaluation and Key Learnings

D. Ruether, L. Watson, Éclair Photitai, 2021, JCO oncology practice.

What is the State of the Science on Physical Activity Interventions for Family Caregivers? A Systematic Review and RE-AIM Evaluation.

K. King-Shier, S. Culos-Reed, C. Cuthbert, 2017, Journal of physical activity & health.

Safe Prescribing Practices: Clinicians' Views on Prescribing Opioids to Patients With Early-Stage Cancer

C. Cuthbert, Y. Tarumi, A. Sinnarajah, 2023, JCO oncology practice.

Interim analysis of a phase I dose escalation trial of ASG-22CE (ASG-22ME; enfortumab vedotin), an antibody drug conjugate (ADC), in patients (Pts) with metastatic urothelial cancer (mUC)

David C. Smith, J. Lang, E. Heath, 2016 .

Renewing caregiver health and wellbeing through exercise (RECHARGE): A randomized controlled trial.

K. King-Shier, C. Cuthbert, S. Culos-Reed, 2016, Contemporary clinical trials.

A randomized phase II study of cabazitaxel (CAB) vs (ABI) abiraterone or (ENZ) enzalutamide in poor prognosis metastatic castration-resistant prostate cancer (mCRPC).

A. Wyatt, B. Tran, M. Annala, 2018, Annals of Oncology.

Using Autoregressive Integrated Moving Average (ARIMA) Modelling to Forecast Symptom Complexity in an Ambulatory Oncology Clinic: Harnessing Predictive Analytics and Patient-Reported Outcomes

D. Ruether, L. Watson, Andrea Deiure, 2021, International journal of environmental research and public health.

Exploring Gender Differences in Self-Reported Physical Activity and Health Among Older Caregivers.

K. King-Shier, S. Culos-Reed, C. Cuthbert, 2017, Oncology nursing forum.

Canadian guideline on genetic screening for hereditary renal cell

S. Pautler, A. Pause, G. Bjarnason, 2013 .

Exploring Gender Differences in Self-Reported Physical Activity and Health Among Older Caregivers.

K. King-Shier, C. Cuthbert, D. Ruether, 2017, Oncology nursing forum.